Camellin Massimo, Guidotti Jacopo Maria, Arba Mosquera Samuel
SEKAL Rovigo Microsurgery Centre, Rovigo, Italy.
Studio Medico Guidotti, Bologna, Italy.
J Optom. 2017 Jan-Mar;10(1):52-62. doi: 10.1016/j.optom.2016.02.001. Epub 2016 Mar 21.
To evaluate the efficacy and safety of Corneal-Wavefront guided transepithelial photorefractive keratectomy (TransPRK) after corneal collagen cross linking (CXL) in keratoconic patients.
In this retrospective, non-comparative, consecutive case series, 39 keratoconic eyes underwent Corneal-Wavefront guided TransPRK for the correction of aberrations at least 4 months after conventional CXL at SEKAL Rovigo Microsurgery Centre, Rovigo, Italy. Two eyes (5%) underwent a secondary laser retreatment for the improvement of post-operative visual acuity and were not included in this retrospective analysis. The mean age of the patients was 35±12 years (19-64 years) at the time of the surgery. Keratron-Scout (Optikon) topographer was used for diagnostic tests and a flying-spot laser (AMARIS; SCHWIND eye-tech-solutions) was used for the refractive surgery. Complete ophthalmic examinations were performed before and after the surgery (4-36 months postoperatively with a mean follow up time of 10±8 months).
Preoperatively, eyes showed irregular astigmatism up to 8D. At last postoperative follow-up, 21 eyes (57%) had UDVA better than 20/40, and six eyes (16%) had UDVA of 20/20. Twenty-three eyes (62%) were within 1.50D of attempted correction in spherical equivalent (mean deviation from target was +1.09±2.36D, range -2.50 to +7.38D). No eye lost 2 Snellen lines of CDVA, and 15 eyes (41%) had an increase of more than 2 lines.
Corneal-Wavefront guided transepithelial PRK ablation profiles after conventional CXL yields to good visual, optical, and refractive results. These treatments are safe and efficacious for the correction of refracto-therapeutic problems in keratoconic patients.
评估圆锥角膜患者角膜胶原交联(CXL)后角膜波前引导的经上皮光屈光性角膜切削术(TransPRK)的疗效和安全性。
在这个回顾性、非对照、连续病例系列中,意大利罗维戈SEKAL罗维戈显微外科中心对39只圆锥角膜眼在传统CXL至少4个月后进行了角膜波前引导的TransPRK,以矫正像差。有2只眼(5%)接受了二次激光治疗以提高术后视力,未纳入该回顾性分析。手术时患者的平均年龄为35±12岁(19 - 64岁)。使用Keratron-Scout(Optikon)角膜地形图仪进行诊断测试,使用飞点激光(AMARIS;SCHWIND eye-tech-solutions)进行屈光手术。在手术前后进行了全面的眼科检查(术后4 - 36个月,平均随访时间为10±8个月)。
术前,眼睛显示不规则散光高达8D。在最后一次术后随访时,21只眼(57%)的最佳矫正视力(UDVA)优于20/40,6只眼(16%)的UDVA为20/20。23只眼(62%)的等效球镜度在预期矫正值的1.50D范围内(与目标的平均偏差为 +1.09±2.36D,范围为 -2.50至 +7.38D)。没有眼睛的矫正视力(CDVA)下降2行,15只眼(41%)的CDVA提高超过2行。
传统CXL后角膜波前引导的经上皮PRK消融模式产生了良好的视觉、光学和屈光效果。这些治疗方法对于矫正圆锥角膜患者的屈光治疗问题是安全有效的。